Hikal Ltd

Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 06 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Hikal Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals. Despite a recent uptick in price, the company’s overall technical indicators and fundamental metrics suggest caution for investors navigating this volatile landscape.

Hikal Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s stock price has declined by 2.94% today, reflecting growing investor caution amid mixed technical signals and a deteriorating overall outlook.

Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Hikal Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent 2.29% rise in its share price to ₹187.30, the company’s overall technical and fundamental outlook remains cautious, with a MarketsMOJO Mojo Grade downgraded to Strong Sell as of 14 Nov 2025.

Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 14 April 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 03 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

The Sensex gained 2.7% on 1 Apr 2026, yet Hikal Ltd outpaced the broader market with a 7.41% surge, reaching an intraday high of Rs 159. This 1.94 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a mere market tailwind.

Hikal Ltd witnessed a robust start to trading on 1 April 2026, opening with a notable gap up of 8.13%, reflecting a positive market sentiment despite the company’s current technical outlook and recent performance trends.

Hikal Ltd’s share price declined to a fresh 52-week low of Rs.150.65 on 30 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a combination of weak financial metrics and broader market headwinds.

Hikal Ltd’s share price declined sharply on 27 Mar 2026, hitting a new 52-week low of Rs.155. This marks a significant drop for the pharmaceutical and biotechnology company, reflecting ongoing pressures in both the stock and broader market environment.

Hikal Ltd experienced significant intraday weakness on 23 Mar 2026, touching a new 52-week low of Rs 156.25, reflecting intense price pressure amid broader sector and market declines. The stock underperformed its Pharmaceuticals & Biotechnology sector peers and the benchmark Sensex, continuing a pronounced downtrend.

Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Hikal Ltd’s share price declined sharply to hit a new 52-week low of Rs.162.5 on 23 March 2026, marking a significant drop amid broader sectoral and market weakness. The stock underperformed both its Pharmaceuticals & Biotechnology sector and the wider market, reflecting ongoing pressures on the company’s financial and technical indicators.

Hikal Ltd’s shares declined sharply to a fresh 52-week low of Rs.165.45 on 19 Mar 2026, marking a significant drop amid a broader sector and market downturn. The stock underperformed the Pharmaceuticals & Biotechnology sector, reflecting ongoing pressures on the company’s financial and technical indicators.

Hikal Ltd’s shares touched a fresh 52-week low of Rs.166 today, marking a significant decline amid persistent downward momentum. The stock’s performance over the past year has been notably weak, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Hikal Ltd’s share price declined to a fresh 52-week low of Rs.169.1 today, marking a continuation of the stock’s downward trajectory amid broader sector underperformance and persistent financial headwinds.